Con­gres­sion­al watch­dog ad­vis­es HHS to im­ple­ment 'post-mar­ket­ing' in­cen­tives to ad­dress dwin­dling an­tibi­ot­ic de­vel­op­ment ef­forts

With the Covid-19 cri­sis ex­pect­ed to shore up an­tibi­ot­ic use with op­por­tunis­tic sec­ondary bac­te­r­i­al in­fec­tions — and po­ten­tial­ly ex­ac­er­bate the rate an­tibi­ot­ic re­sis­tance — a con­gres­sion­al watch­dog has put to­geth­er a list of rec­om­men­da­tions to sort out the chal­lenges af­fect­ing an­tibi­ot­ic stew­ard­ship, track rates of drug re­sis­tance, and fix the ‘bro­ken’ mar­ket for an­tibi­otics.

While bac­te­r­i­al pathogens mu­tate and grow re­sis­tant to the ex­ist­ing crop of an­tibi­otics, dri­ven by un­bri­dled use in hu­mans and live­stock — the in­dus­try play­ers con­tribut­ing to the ar­se­nal of an­timi­cro­bials are fast dwin­dling, and the pipeline for new an­tibi­otics is em­bar­rass­ing­ly sparse, the WHO has warned.

The US Gov­ern­ment Ac­count­abil­i­ty Of­fice, on Wednes­day, is­sued a re­port en­com­pass­ing da­ta from doc­u­ments and in­ter­views with agency of­fi­cials and ex­perts, find­ing that there are var­i­ous chal­lenges in im­ple­ment­ing ap­pro­pri­ate an­tibi­ot­ic use in the Unit­ed States, for in­stance, fed­er­al re­quire­ments for an­tibi­ot­ic stew­ard­ship pro­grams ap­ply to on­ly cer­tain health care fa­cil­i­ties, and in­cen­tives for doc­tors to adopt an­tibi­ot­ic stew­ard­ship ac­tiv­i­ties are op­tion­al.

Source: GAO, 2020

Click on the im­age to see the full-sized ver­sion

The re­port rec­og­nized that al­though there is a raft of in­cen­tives in place to push drug­mak­ers to de­vel­op an­tibi­otics, such as fund­ing sup­port through the Bio­med­ical Ad­vanced Re­search and De­vel­op­ment Au­thor­i­ty (BAR­DA) and reg­u­la­to­ry re­forms such as the Lim­it­ed Pop­u­la­tion Path­way for An­tibac­te­r­i­al and An­ti­fun­gal Drugs (LPAD) —  there is a des­per­ate need for the pas­sage of “pull in­cen­tives,” or pol­i­cy mea­sures to in­crease the val­ue of a mar­ket­ed an­tibi­ot­ic by re­ward­ing drug­mak­ers on­ly af­ter their an­tibi­ot­ic is ap­proved.

Ex­ist­ing in­cen­tives, “while well-in­ten­tioned…ap­pear to have been in­suf­fi­cient, as they fo­cused ex­clu­sive­ly on bol­ster­ing the de­vel­op­ment pipeline with­out re­mov­ing the block­age cre­at­ed by is­sues with pay­ment,” CMS ad­min­is­tra­tor Seema Ver­ma con­ced­ed last Au­gust.

There has been a slew of bank­rupt­cies in the an­tibi­ot­ic sec­tor, as com­pa­nies see their val­ue go up in smoke as fee­ble sales frus­trat­ed growth. The long, ar­du­ous and ex­pen­sive path to an­tibi­ot­ic ap­proval — com­pli­cat­ed by is­sues of clin­i­cal tri­al en­roll­ment (there are no rapid di­ag­nos­tic tests to iden­ti­fy in­fec­tions,  and it is hard to re­cruit pa­tients in clin­i­cal tri­als to test an­tibi­otics that tar­get re­sis­tant bac­te­ria) of­fers lit­tle fi­nan­cial gain as treat­ments are typ­i­cal­ly priced cheap­ly. The me­di­an an­nu­al sales for brand name an­tibi­otics be­tween 2011 and 2015 ranged from $24 mil­lion to $75 mil­lion, where­as an­nu­al sales for most new, brand-name on­col­o­gy drugs were more than $500 mil­lion dur­ing the same pe­ri­od, the GAO re­port said.

For one of the biggest threats to glob­al health, the li­on’s share of an­tibi­ot­ic de­vel­op­ment is now tak­ing place in a hand­ful of labs of small bio­phar­ma com­pa­nies as a ma­jor­i­ty of their larg­er coun­ter­parts fo­cus on more lu­cra­tive en­deav­ors such as on­col­o­gy. Big Phar­ma has large­ly re­treat­ed from an­tibi­otics, and on­ly a hand­ful re­main in the space — in­clud­ing Mer­ck, Roche and GSK — down from more than 20 in the 1980s.

For­mer FDA com­mis­sion­er Scott Got­tlieb, in 2018, sug­gest­ed a “li­cens­ing mod­el” in which acute care in­sti­tu­tions that pre­scribe an­timi­cro­bial med­i­cines pay a fixed li­cens­ing fee for ac­cess to these drugs, grant­i­ng them the right to use a cer­tain num­ber of an­nu­al dos­es. Last year, the CMS un­veiled a pro­pos­al to re­struc­ture the pay­ment ap­pa­ra­tus to res­cue ex­ist­ing an­tibi­ot­ic man­u­fac­tur­ers, by clas­si­fy­ing drug re­sis­tance in a way that would com­pel high­er pay­ments to hos­pi­tals treat­ing pa­tients with an­timi­cro­bial re­sis­tance, and craft­ing a path­way for doc­tors to pre­scribe ap­pro­pri­ate new an­tibi­otics with­out dis­rupt­ing hos­pi­tal bud­gets. Un­der the cur­rent sys­tem, hos­pi­tals bun­dle to­geth­er the costs of all the ser­vices for a giv­en di­ag­no­sis, which tends to in­cen­tivize hos­pi­tals to pre­scribe cheap­er, gener­ic an­tibi­otics that are not en­gi­neered to tack­le drug-re­sis­tant in­fec­tions.

The GAO made 8 rec­om­men­da­tions fix the myr­i­ad of prob­lems, in­clud­ing that the CDC should de­vel­op a plan for con­sol­i­dat­ed re­ports of an­tibi­ot­ic re­sis­tance in pri­or­i­ty pathogens at reg­u­lar in­ter­vals; the HHS should iden­ti­fy lead­er­ship and clar­i­fy roles and re­spon­si­bil­i­ties among HHS agen­cies to as­sess the clin­i­cal out­comes of di­ag­nos­tic test­ing for iden­ti­fy­ing an­tibi­ot­ic-re­sis­tant bac­te­ria; and im­por­tant­ly that the HHS should come up with a strate­gic frame­work to fur­ther in­cen­tivize an­tibi­otics for drug-re­sis­tant in­fec­tions, in­clud­ing through the use of post­mar­ket fi­nan­cial in­cen­tives.

Each rec­om­men­da­tion apart from the post­mar­ket fi­nan­cial in­cen­tives was ac­cept­ed by the var­i­ous agen­cies. “HHS not­ed that, while it agrees that ad­di­tion­al in­cen­tives are need­ed to ad­dress the lim­it­ed pipeline for nov­el and in­no­v­a­tive treat­ments to com­bat an­tibi­ot­ic re­sis­tance, it is still con­duct­ing analy­ses to un­der­stand whether post­mar­ket in­cen­tives should be in­clud­ed as a com­po­nent of its forth­com­ing strate­gic frame­work to fur­ther in­cen­tivize the de­vel­op­ment of new treat­ments. How­ev­er, HHS did not spec­i­fy when its frame­work would be re­leased,” the GAO re­port said.

The au­thors, how­ev­er, stood by their call: “We be­lieve our rec­om­men­da­tion is still war­rant­ed.”

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Michael Corbo, Pfizer CDO of inflammation & immunology

UP­DAT­ED: Plan­ning ahead for crowd­ed ul­cer­a­tive col­i­tis mar­ket, Pfiz­er spells out PhI­II da­ta on $6.7B Are­na drug

Pfizer has laid out the detailed results behind its boast that etrasimod — the S1P receptor modulator at the center of its $6.7 billion buyout of Arena Pharma — is the winner of the class, potentially leapfrogging an earlier entrant from Bristol Myers Squibb.

Pivotal data from the ELEVATE program in ulcerative colitis — which consists of two Phase III trials, one lasting 52 weeks and the other just 12 weeks — illustrate an “encouraging balance of efficacy and safety,” according to Michael Corbo, chief development officer of inflammation & immunology at Pfizer. The company is presenting the results as a late breaker at Digestive Disease Week.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

An NYU surgeon transplants an engineered pig kidney into the outside of a brain-dead patient (Joe Carrotta/NYU Langone Health)

'Xeno­trans­plan­ta­tion is com­ing': New NE­JM pa­per gives de­tailed look in­to 2 pig-to-hu­man kid­ney trans­plant cas­es

The thymokidney is a curious organ, if you could call it that. It’s a sort of Frankensteinian creation — a system of pig thymus embedded underneath the outer layer of a pig’s kidney, made for human transplantation.

In the first case of pig-to-human xenotransplantation of a kidney into a brain-dead patient, the thymokidney quietly featured front and center.

In that experiment, which took place in September of last year, NYU researchers led by Robert Montgomery sutured a pig thymokidney onto the leg of a brain-dead 66-year-old woman. That case was widely reported on by a horde of major media outlets, including the New York Times, the BBC, and an in-depth feature by USA Today.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Vlad Coric, Biohaven CEO

UP­DAT­ED: Fresh off $11.6B sale to Pfiz­er, New Bio­haven hits Phase III set­back just weeks af­ter Vlad Coric chalked up promise

When Pfizer bought up Biohaven’s migraine portfolio in the largest M&A deal of the year earlier this month, Biohaven CEO Vlad Coric promised the rest of the pipeline, which will live on under the umbrella of New Biohaven, still has a lot to offer. But that vision took a dent Monday as the drugmaker revealed it’s once again flopped on troriluzole.

The glutamate regulator failed to meet the primary endpoint on a Phase III study in patients with spinocerebellar ataxia, an inherited disorder that impairs a person’s ability to walk, speak and swallow. SCA can also lead to premature death.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Mihael Polymeropoulos, Vanda Pharmaceuticals CEO

Phar­ma com­pa­ny con­tin­ues its FDA law­suit spree, this time af­ter agency de­nies fast-track des­ig­na­tion

Vanda Pharmaceuticals is making a name for itself, at least in terms of suing the FDA.

The DC-headquartered firm on Monday filed its latest suit against the agency, with the company raising concerns over the FDA’s failure to grant a fast track designation for Vanda’s potential chronic digestive disorder drug tradipitant, which is a neurokinin 1 receptor antagonist.

Specifically, Vanda said FDA’s “essential point” in its one-page denial letter on the designation pointed to “the lack of necessary safety data,” which was “inconsistent with the criteria for … Fast Track designation.”

Mod­er­na seeks to dis­miss Al­ny­lam suit over Covid-19 vac­cine com­po­nent, claim­ing wrong venue

RNAi therapeutics juggernaut Alnylam Pharmaceuticals made a splash in March when it sued and sought money from both Pfizer and Moderna regarding their use of Alnylam’s biodegradable lipids, which Alnylam claims have been integral to the way both companies’ mRNA-based Covid-19 vaccines work.

But now, Moderna lawyers are firing back, telling the same Delaware district court that Alnylam’s claims can only proceed against the US government in the Court of Federal Claims because of the way the company’s contract is set up with the US government. The US has spent almost $10 billion on Moderna’s Covid-19 vaccine so far.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

(Credit: Shutterstock)

Cracks in the fa­cade: Is phar­ma's pan­dem­ic ‘feel good fac­tor’ wan­ing?

The discordant effects of the Covid-19 pandemic on pharma reputation continues. While the overall industry still retains a respectable halo from its Covid-19 quick response and leadership, a new patient group study reveals a different story emerging in the details.

On one hand, US patient advocacy groups rated the industry higher-than-ever overall. More than two-thirds (67%) of groups gave the industry a thumbs up for 2021, a whopping 10 percentage point increase over the year before, according to the PatientView annual study, now in its 9th year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.

Saqib Islam, SpringWorks CEO

Pfiz­er spin­out Spring­Works will ship its first drug to the FDA be­fore year’s end with PhI­II win

SpringWorks Therapeutics thinks it has cemented the backbone for its first “pipeline-in-a-product” oncology treatment and will send it to the FDA before the clock strikes 2023 with a Phase III win on Tuesday.

The oral gamma secretase inhibitor, dubbed nirogacestat, beat placebo on the primary goal of progression-free survival in adults with progressing desmoid tumors.

The soft-tissue tumors can lead to long-lasting pain, disfigurement and amputation, and there are currently no approved meds for the rare oncology indication. The tumors typically impact patients aged 20 to 44 years old and disproportionately affect women at rates 2 to 3 times higher, with up to a total of 1,650 new cases diagnosed in the US annually, according to SpringWorks.

Robert Califf (Michael Brochstein/Sipa USA via AP Images)

House Re­pub­li­cans at­tack Chi­na-on­ly da­ta in FDA sub­mis­sions, seek new in­ves­ti­ga­tion in­to re­search in­spec­tions

Three Republican representatives are calling on the FDA to take a closer look at the applications including only clinical data from China.

The letter to FDA commissioner Rob Califf late last week comes as the agency recently rejected Eli Lilly’s anti-PD-1 antibody, which attempted to bring China-only data but ran into a bruising adcomm that may crush the hopes of any other companies looking to bring cheaper follow-ons based only on Chinese data.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,600+ biopharma pros reading Endpoints daily — and it's free.